

From: OncLive <edigest@onclive.com>

Sent: <Day, Month xx, 2020>

To: <<Email Address>>

Subject: Live Broadcast Registration Confirmation: A New First-Line Combination for Advanced Renal Cell Carcinoma

[No Images? Click here](#)

Dear [Full Name],

We are pleased to confirm your registration to view this live broadcast to gain an expert perspective on the changing therapeutic landscape and learn about a new first-line combination approach for patients with advanced renal cell carcinoma.

Thank you for your participation!

Date: [Month/Day/20]

Time: [XX:XXpm]

VIEW LIVE BROADCAST

This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.

Join Our RCC Experts:



Daniel James George, MD

Professor of Medicine and Surgery
Director of GU Oncology
Co-Leader, DCI Center for Prostate & Urologic Cancers
Duke University Medical Center



Ulka Vaishampayan, MD

Professor of Medicine
Division of Hematology/Oncology
University of Michigan



Sumanta Kumar Pal, MD

Clinical Professor
Department of Medical Oncology & Experimental
Therapeutics
City of Hope

In this Live Broadcast Dr. George, Dr. Vaishampayan, and Dr. Pal will:



Review mechanisms of action of a multitargeted approach to aRCC treatment



Explore key efficacy and safety data for a new first-line combination regimen



Provide expert perspectives on clinical trial data



Share clinical insights through a live Q&A

VIEW LIVE BROADCAST

OncLive®

EXELIXIS®

CA-1715 01/21

This program is not certified for Continuing Medical Education credit.

This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.

OncLive® – an MJH Life Sciences™ brand
Copyright 2021 © Intellisphere, LLC
2 Clarke Dr | Suite 100 | Cranbury, NJ | 08512

[Preferences](#) | [Unsubscribe](#)

Forward

From: OncLive <edigest@onclive.com>
Sent: <Day, Month xx, 2020>
To: <<Email Address>>
Subject: Live Broadcast Registration Confirmation: A New First-Line Combination for Advanced Renal Cell Carcinoma

No Images? [Click here](#)

Dear [Full Name],

We are pleased to confirm your registration to view this live broadcast to gain an expert perspective on the changing therapeutic landscape and learn about a new first-line combination approach for patients with advanced renal cell carcinoma.

Thank you for your participation!

Date: [Month/Day/20]

Time: [XX:XXpm]

VIEW LIVE BROADCAST

This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.

Join Our RCC Experts:



Daniel James George, MD
Professor of Medicine and Surgery
Director of GU Oncology
Co-Leader, DCI Center for Prostate & Urologic Cancers
Duke University Medical Center



Ulka Vaishampayan, MD
Professor of Medicine
Division of Hematology/Oncology
University of Michigan



Sumanta Kumar Pal, MD
Clinical Professor
Department of Medical Oncology & Experimental
Therapeutics
City of Hope

In this Live Broadcast Dr. George, Dr. Vaishampayan, and Dr. Pal will:



Review mechanisms of action of a multitargeted approach to aRCC treatment



Explore key efficacy and safety data for a new first-line combination regimen



Provide expert perspectives on clinical trial data



Share clinical insights through a live Q&A

VIEW LIVE BROADCAST

OncLive®

EXELIXIS®

CA-1715 01/21
This program is not certified for Continuing Medical Education credit.

This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.

OncLive® – an MJH Life Sciences™ brand
Copyright 2021 © Intellisphere, LLC
2 Clarke Dr | Suite 100 | Cranbury, NJ | 08512

[Preferences](#) | [Unsubscribe](#)

Forward